Adia Nutrition, Inc. is engaged in the creation of probiotics. The company is headquartered in Winter Park, Florida. The company went IPO on 2004-03-23. The Company’s divisions include supplement division and medical division. The supplement division provides organic supplements. The medical division establishes clinics that specialize in stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Adia Med of Winter Park, LLC, its subsidiary, operates clinic to perform treatments, and Adia Labs, LLC, its subsidiary, procures and sells the products relating to these procedures. Adia Med is conducting a nationwide rollout of satellite locations offering Umbilical Cord Stem Cell (UCB-SC) and exosome treatments, like AdiaVita from Adia Labs LLC, with at least 100 million stem cells and three trillion exosomes per unit. These therapies address chronic inflammation, autoimmune disorders, and orthopedic issues. The firm has approximately 18% equity position in Cement Factory, LLC.
최신 재무제표(Form-10K)에 따르면, Ensurge Inc의 총 자산은 $0이며, 순손실입니다.
ADIA의 주요 재무 비율은 무엇인가요?
Ensurge Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Adia Nutrition Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Ensurge Inc 주요 수익원은 Elections Technology Software and Hardware이며, 최신 수익 발표에서 수익은 1,273,504입니다. 지역별로는 United States이 Ensurge Inc의 주요 시장이며, 수익은 1,273,504입니다.